Transcription and translation are primary targets of Pim kinase inhibitor SGI-1776 in mantle cell lymphoma

PIM2 inhibition as a rational therapeutic approach in B-cell lymphoma

(2011) C. Gomez-Abad et al.   BLOOD

Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia

(2011) L. S. Chen et al.   BLOOD

Targeting PIM kinase activity significantly augments the efficacy of cytarabine

(2011) Kevin R. Kelly et al.   BRITISH JOURNAL OF HAEMATOLOGY

Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma

(2011) Jonathan H. Schatz et al.   JOURNAL OF EXPERIMENTAL MEDICINE

The serine/threonine kinase Pim-2 is a novel anti-apoptotic mediator in myeloma cells

(2011) J Asano et al.   LEUKEMIA

Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era

(2010) P. Perez-Galan et al.   BLOOD

A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma

(2010) T E Witzig et al.   LEUKEMIA

Mantle cell lymphoma: Report of the 2009 Mantle Cell Lymphoma Consortium Workshop

(2010) Michael E. Williams et al.   LEUKEMIA & LYMPHOMA

Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells

(2009) L. S. Chen et al.   BLOOD

Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia

(2009) J. Tamburini et al.   BLOOD

Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes

(2009) S. M. Mumenthaler et al.   MOLECULAR CANCER THERAPEUTICS

Bone Marrow Involvement by Marginal Zone B-Cell Lymphomas of Different Types

(2008) Kedar V. Inamdar et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Mcl-1: the 1 in CLL

(2008) V. Gandhi et al.   BLOOD

Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers

(2008) C. Pepper et al.   BLOOD

Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group

(2008) C. H. Geisler et al.   BLOOD

Pim Kinases Promote Cell Cycle Progression by Phosphorylating and Down-regulating p27Kip1 at the Transcriptional and Posttranscriptional Levels

(2008) D. Morishita et al.   CANCER RESEARCH

Elevated Levels of Oncogenic Protein Kinase Pim-1 Induce the p53 Pathway in Cultured Cells and Correlate with Increased Mdm2 in Mantle Cell Lymphoma

(2008) Carol Hogan et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells

(2008) S Gobessi et al.   LEUKEMIA

Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study

(2008) Eric D. Hsi et al.   LEUKEMIA & LYMPHOMA

Pim kinase-dependent inhibition of c-Myc degradation

(2008) Y Zhang et al.   ONCOGENE

Multiple signaling pathways promote B lymphocyte stimulator dependent B-cell growth and survival

(2007) R. T. Woodland et al.   BLOOD